CA2335366A1 - Compositions et methodes de traitement d'une cholesterolemie elevee - Google Patents

Compositions et methodes de traitement d'une cholesterolemie elevee Download PDF

Info

Publication number
CA2335366A1
CA2335366A1 CA002335366A CA2335366A CA2335366A1 CA 2335366 A1 CA2335366 A1 CA 2335366A1 CA 002335366 A CA002335366 A CA 002335366A CA 2335366 A CA2335366 A CA 2335366A CA 2335366 A1 CA2335366 A1 CA 2335366A1
Authority
CA
Canada
Prior art keywords
geranylgeranyl
geranylgeraniol
hmg
coa reductase
reductase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002335366A
Other languages
English (en)
Inventor
Edward M. Scolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9817167.1A external-priority patent/GB9817167D0/en
Application filed by Individual filed Critical Individual
Publication of CA2335366A1 publication Critical patent/CA2335366A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des méthodes de traitement d'une cholestérolémie élevée chez un mammifère tout en évitant l'apparition d'effets secondaires indésirables tels que la myopathie. Ces compositions contiennent une combinaison d'une dose pharmaceutiquement efficace d'un inhibiteur de la 3-hydroxy-3-méthyl-glutaryle coenzyme A (HMG-CoA) réductase et d'un composé de géranylgéraniol. Ces compositions sont destinées à être administrées à un mammifère nécessitant un tel traitement.
CA002335366A 1998-06-24 1999-06-21 Compositions et methodes de traitement d'une cholesterolemie elevee Abandoned CA2335366A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9052798P 1998-06-24 1998-06-24
US60/090,527 1998-06-24
GB9817167.1 1998-08-06
GBGB9817167.1A GB9817167D0 (en) 1998-08-06 1998-08-06 Compositions and methods for treating elevated blood cholesterol
PCT/US1999/013887 WO1999066929A1 (fr) 1998-06-24 1999-06-21 Compositions et methodes de traitement d'une cholesterolemie elevee

Publications (1)

Publication Number Publication Date
CA2335366A1 true CA2335366A1 (fr) 1999-12-29

Family

ID=26314174

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002335366A Abandoned CA2335366A1 (fr) 1998-06-24 1999-06-21 Compositions et methodes de traitement d'une cholesterolemie elevee

Country Status (5)

Country Link
EP (1) EP1089731A4 (fr)
JP (1) JP2002518448A (fr)
AU (1) AU754767B2 (fr)
CA (1) CA2335366A1 (fr)
WO (1) WO1999066929A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5041400A (en) 1999-05-24 2000-12-12 America River Nutrition, Inc. Tocotrienols and geranylgeraniol from LTiGTbixa orellanaLT/iGT byproducts
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (fr) 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
EP1624880B1 (fr) * 2003-04-08 2018-12-19 Barrie Tan Compositions d'extrait de rocou contenant des geranylgeraniols pour utilisation dans la diminution de niveau sanguin de triglyceride
EP2400840A4 (fr) * 2009-02-24 2012-08-01 Madeira Therapeutics Formulations de statine liquide
WO2010126579A1 (fr) * 2009-04-27 2010-11-04 Beth Israel Deaconess Medical Center Méthodes et compositions utilisées pour le traitement et le diagnostic des myopathies provoquées par les statines
WO2013130654A1 (fr) * 2012-02-29 2013-09-06 Coyote Pharmaceuticals, Inc. Gga et dérivés de gga, compositions de ceux-ci et procédés pour le traitement de maladies neurodégénératives, comprenant une paralysie, les comprenant
WO2014055440A1 (fr) * 2012-10-01 2014-04-10 Coyote Pharmaceuticals, Inc. Préparation de gga et de leurs dérivés et leur co-cristallisation avec l'urée ou la thio-urée
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8105781A1 (es) * 1979-07-27 1981-06-16 Sankyo Co Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos.
US4933165A (en) * 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
WO1991005754A2 (fr) * 1989-10-13 1991-05-02 Medafor Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophiques et cytoprotectrices, et compositions pharmaceutiques les contenant
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
IL112639A0 (en) * 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
IT1276162B1 (it) * 1995-11-23 1997-10-27 Baldacci Lab Spa Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
JPH1087480A (ja) * 1996-09-13 1998-04-07 Eisai Co Ltd 抗動脈硬化治療剤
US5763646A (en) * 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Process for manufacturing simvastatin from lovastatin or mevinolinic acid

Also Published As

Publication number Publication date
EP1089731A1 (fr) 2001-04-11
AU4698999A (en) 2000-01-10
WO1999066929A1 (fr) 1999-12-29
EP1089731A4 (fr) 2003-06-18
AU754767B2 (en) 2002-11-21
JP2002518448A (ja) 2002-06-25

Similar Documents

Publication Publication Date Title
AU754767B2 (en) Compositions and methods for treating elevated blood cholesterol
ES2632967T3 (es) Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
US8481570B2 (en) 1-methylnicotinaide derivatives and formulations of treatment of lipoprotein abnormalities
EP1660066B1 (fr) Composition pharmaceutique comprenant une combinaison de metformine et une statine
US12115137B2 (en) Synergistic combinations of atorvastatin and cannabidiol (CBD)
CA2336192A1 (fr) Compositions et methodes de traitement d'une cholesterolemie elevee
US9642860B2 (en) Combinations of corroles and statins
EP0373507A1 (fr) Combinaison d'un inhibiteur de HMG-CoA réductase et autres agents réduisant le cholestérol du sérum et méthode pour diminuer le cholestérol du sérum utilisant celle combinaison
US20070166321A1 (en) Compositions and Methods for Reducing Cholesterol and Inflammation
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
US20040023919A1 (en) Blood lipid ameliorant composition
KR20050092568A (ko) 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체
US5461072A (en) Use of aryl hydroxyurea compounds for the treatment of atherosclerosis
Jurkowski Statins regulate IL-1β-induced RANKL and OPG production by human gingival fibroblasts
CA2494801A1 (fr) Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase
WO2002098353A2 (fr) Compositions et methodes d'inhibition de la resorption osseuse
JP2007063224A (ja) チロシナーゼ活性阻害剤
RU2008144912A (ru) Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов
HK1154784A (en) Pharmaceutical composition comprising racetam and carniting and process for its preparation

Legal Events

Date Code Title Description
FZDE Dead